623 related articles for article (PubMed ID: 2910757)
21. Factors influencing the development of Barrett's epithelium in the esophageal remnant postesophagectomy.
O'Riordan JM; Tucker ON; Byrne PJ; McDonald GS; Ravi N; Keeling PW; Reynolds JV
Am J Gastroenterol; 2004 Feb; 99(2):205-11. PubMed ID: 15046206
[TBL] [Abstract][Full Text] [Related]
22. Screening and surveillance for complications related to gastroesophageal reflux disease.
Spechler SJ
Am J Med; 2001 Dec; 111 Suppl 8A():130S-136S. PubMed ID: 11749938
[TBL] [Abstract][Full Text] [Related]
23. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus.
Phillips RW; Frierson HF; Moskaluk CA
Am J Surg Pathol; 2003 Nov; 27(11):1442-7. PubMed ID: 14576477
[TBL] [Abstract][Full Text] [Related]
24. Barrett's esophagus and risk of esophageal adenocarcinoma.
Cossentino MJ; Wong RK
Semin Gastrointest Dis; 2003 Jul; 14(3):128-35. PubMed ID: 14653412
[TBL] [Abstract][Full Text] [Related]
25. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.
Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J
Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858
[TBL] [Abstract][Full Text] [Related]
26. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
[TBL] [Abstract][Full Text] [Related]
27. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus.
Levine DS; Haggitt RC; Blount PL; Rabinovitch PS; Rusch VW; Reid BJ
Gastroenterology; 1993 Jul; 105(1):40-50. PubMed ID: 8514061
[TBL] [Abstract][Full Text] [Related]
28. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation.
Chinyama CN; Marshall RE; Owen WJ; Mason RC; Kothari D; Wilkinson ML; Sanderson JD
Histopathology; 1999 Dec; 35(6):517-24. PubMed ID: 10583575
[TBL] [Abstract][Full Text] [Related]
29. [The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].
Endzinas Z; Mickevicius A; Kiudelis M
Zentralbl Chir; 2004 Apr; 129(2):99-103. PubMed ID: 15106039
[TBL] [Abstract][Full Text] [Related]
30. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
[TBL] [Abstract][Full Text] [Related]
31. Short-segment Barrett's esophagus: A prevalent complication of gastroesophageal reflux disease with malignant potential.
Clark GW; Ireland AP; Peters JH; Chandrasoma P; DeMeester TR; Bremner CG
J Gastrointest Surg; 1997; 1(2):113-22. PubMed ID: 9834337
[TBL] [Abstract][Full Text] [Related]
32. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
Avidan B; Sonnenberg A; Schnell TG; Chejfec G; Metz A; Sontag SJ
Am J Gastroenterol; 2002 Aug; 97(8):1930-6. PubMed ID: 12190156
[TBL] [Abstract][Full Text] [Related]
33. Origins of Metaplasia in Barrett's Esophagus: Is this an Esophageal Stem or Progenitor Cell Disease?
Zhang W; Wang DH
Dig Dis Sci; 2018 Aug; 63(8):2005-2012. PubMed ID: 29675663
[TBL] [Abstract][Full Text] [Related]
34. Histology of metaplasia and dysplasia in Barrett's esophagus.
Yerian L
Surg Oncol Clin N Am; 2009 Jul; 18(3):411-22. PubMed ID: 19500733
[TBL] [Abstract][Full Text] [Related]
35. Epithelial cell proliferative activity of Barrett's esophagus: methodology and correlation with traditional cancer risk markers.
Peters FT; Ganesh S; Kuipers EJ; de Jager-Krikken A; Karrenbeld A; Harms G; Sluiter WJ; Koudstaal J; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
Dig Dis Sci; 1998 Jul; 43(7):1501-6. PubMed ID: 9690386
[TBL] [Abstract][Full Text] [Related]
36. Barrett's disease: pathophysiology of metaplasia and adenocarcinoma.
Pera M; Trastek VF; Pairolero PC; Cardesa A; Allen MS; Deschamps C
Ann Thorac Surg; 1993 Nov; 56(5):1191-7. PubMed ID: 8239829
[TBL] [Abstract][Full Text] [Related]
37. What the gastroenterologist needs to know about the histology of Barrett's esophagus.
Odze RD
Curr Opin Gastroenterol; 2011 Jul; 27(4):389-96. PubMed ID: 21543978
[TBL] [Abstract][Full Text] [Related]
38. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
Wani S; Rubenstein JH; Vieth M; Bergman J
Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
[TBL] [Abstract][Full Text] [Related]
39. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
[TBL] [Abstract][Full Text] [Related]
40. Barrett's metaplasia and adenocarcinoma of the esophagus and gastroesophageal junction.
Thompson JJ; Zinsser KR; Enterline HT
Hum Pathol; 1983 Jan; 14(1):42-61. PubMed ID: 6832749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
